EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment

Nancy Agmon-Levin, Stanislav Ignatenko, Alexander Gordienko, Josefina Cortés-Hernández, Pongthorn Narongroeknawin, Katarzyna Romanowska-Próchnicka, Nan Shen, Hana Ciferská, Masanari Kodera, Wei J Cheng-Chung, Piotr Leszczynski, Joung-Liang Lan und 23 weitere

Annals of the Rheumatic Diseases · 2026-03 · 85 (3) · 476-488

DOI: 10.1016/j.ard.2025.11.015 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of the Rheumatic Diseases, 2026-03. Verfasst von Nancy Agmon-Levin und 34 weiteren Autor:innen. Beteiligte Einrichtung: Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Aviv Univ, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Antibodies, Monoclonal, B-Lymphocytes, B-Cell Activation Factor Receptor. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharma, Novartis AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: B cell depletion or B cell activating factor (BAFF) blockade has shown benefits in systemic lupus erythematosus (SLE). We compared ianalumab, a monoclonal antibody targeting BAFF receptor (BAFF-R)-expressing B cells to lyse B cells and block BAFF-R, with placebo for SLE treatment combined with standard therapies. METHODS: Patients with active SLE were randomised (1:1) to monthly subcutaneous ianalumab 300 mg or placebo. The primary outcome was a composite of SLE Responder Index (SRI)-4 at week 28 in patients successfully achieving corticosteroid (CS) tapering criteria. Patients subsequently received open-label (OL) ianalumab until week 48, followed by exploratory assessments at week 52 and off-treatment to week 68. Safety monitoring continued until B cell recovery. This report describes interim analyses conducted on the week 68 dataset. RESULTS: Sixty-seven patients were randomised and received blinded treatments until week 28. The primary composite endpoint was more frequently achieved with ianalumab vs placebo: 15/34 (44.1%) vs 3/33 (9.1%), with responses sustained to week 52 and replicated by placebo transitioned to OL ianalumab: 15/33 (45.5%) and 13/32 (40.6%). Positive treatment effects were consistently observed across other lupus disease activity outcomes (SRI-6, Definition of Remission in SLE, Lupus Low Disease Activity State, flare reduction, and CS use) at week 28, with clinical benefits until weeks 52 and 68. Ianalumab was not associated with increased serious adverse events or serious infections. Nonserious local injection site reactions occurred more frequently with ianalumab. CONCLUSIONS: At week 28, reduced disease activity was observed in patients with SLE receiving ianalumab plus standard therapies compared with those receiving standard therapies alone, with sustained benefits with further treatment until 1 year, which was well tolerated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicAntibodies, MonoclonalB-LymphocytesB-Cell Activation Factor ReceptorLymphocyte DepletionHumansFemaleMaleAdultDouble-Blind MethodMiddle AgedAntibodies, Monoclonal, HumanizedTreatment OutcomeSeverity of Illness IndexYoung Adult

Substanzen

Antibodies, Monoclonal, HumanizedAntibodies, MonoclonalB-Cell Activation Factor Receptor

Autor:innen und Institutionen

  • Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Aviv Univ, Tel Aviv, Israel.
  • Charité Research Organisation GmbH, Berlin, Germany.
  • Department of Hospital Therapy, SM Kirov Military Medical Academy, St Petersburg, Russia.
  • Lupus Unit, Rheumatology Department, Vall d'Hebron Hospitals, Barcelona, Spain.
  • Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand.
  • Department of Biophysics, Physiology and Pathophysiology, Medical University of Warsaw, Warsaw, Poland.

Förderung

  • Novartis Pharma
  • Novartis AG

Zitieren

APA

Agmon-Levin, N., Ignatenko, S., Gordienko, A., Cortés-Hernández, J., Narongroeknawin, P., Romanowska-Próchnicka, K., Shen, N., Ciferská, H., Kodera, M., Cheng-Chung, W. J., Leszczynski, P., Lan, J. L., Mysler, E., Wojciechowski, R., Tarr, T., Vishneva, E., Chen, Y. H., Kaneko, Y., Finzel, S., …, & Oliver, S. J. (2026). B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment. Annals of the Rheumatic Diseases, 85(3), 476-488. https://doi.org/10.1016/j.ard.2025.11.015

Vancouver

Agmon-Levin N, Ignatenko S, Gordienko A, Cortés-Hernández J, Narongroeknawin P, Romanowska-Próchnicka K, et al. B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment. Annals of the Rheumatic Diseases. 2026;85(3):476-488. doi:10.1016/j.ard.2025.11.015

BibTeX
@article{AgmonLevin2026,
  author = {Agmon-Levin, Nancy and Ignatenko, Stanislav and Gordienko, Alexander and Cortés-Hernández, Josefina and Narongroeknawin, Pongthorn and Romanowska-Próchnicka, Katarzyna and Shen, Nan and Ciferská, Hana and Kodera, Masanari and Cheng-Chung, Wei J and Leszczynski, Piotr and Lan, Joung-Liang and Mysler, Eduardo and Wojciechowski, Rafal and Tarr, Tunde and Vishneva, Elena and Chen, Yi-Hsing and Kaneko, Yuko and Finzel, Stephanie and Hoi, Alberta and Okada, Masato and Koolvisoot, Ajchara and Lee, Shin-Seok and Lie, Dai and Kaneko, Hiroshi and Rojkovich, Bernadette and Sun, Lingyun and Zotkin, Eugeny and Viallard, Jean-Francoise and López, Berta Paula Magallares and Ghanshani, Swati Aashish and Lau, Carol and Avrameas, Alexandre and Sips, Carole and Oliver, Stephen John},
  title = {B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  volume = {85},
  number = {3},
  pages = {476--488},
  doi = {10.1016/j.ard.2025.11.015}
}
Kostenlos starten →